Introduction Since their introduction, drug-eluting stents (DES) have revolutionized percutaneous treatment of coronary artery disease with rates of in-stent restenosis of between 2 and 10% [] and ...

did not outshine standard treatment with second generation drug-eluting stents (DES) as they were expected to, in a surprise ...

A novel, polymer-free, dual-drug-eluting stent (DES) has shown improved or comparable efficacy to two commercially available, permanent polymer stents: the sirolimus-eluting stent (SES ...

A bioresorbable vascular scaffold (BRS) with highly aligned microstructure and small-crystallite crystallinity can avoid high ...

A study has found that sirolimus-coated balloons vs thin drug-eluting stents in in-stent restenosis show similar favorable clinical outcomes.

Drug-coated balloon (DCB) angioplasty as the initial strategy for de novo coronary artery stenoses didn't measure up to ...

The DynamX Bioadaptor device was noninferior to DES for TLF overall, but a landmark analysis reveals a potential strength.

Undergoing percutaneous coronary intervention (PCI) for narrowed arteries with a novel bioadaptor is at least as effective as a contemporary drug-eluting ... generation DES and bare metal stents.

This is certainly an interesting and hypothesis-generating finding that may indicate an efficacy advantage for the BioMatrix flex stent platform and/or the Biolimus A9 drug, or may hint at an ...